China Journal of Oral and Maxillofacial Surgery ›› 2017, Vol. 15 ›› Issue (4): 377-381.
• Review Articles • Previous Articles Next Articles
Online:2017-08-10
Published:2017-08-14
CLC Number:
| [1] 郭伟. 头颈肿瘤诊断治疗学[M]. 北京: 人民军医出版社, 2013: 138-148. [2] Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino- and Native-American populations[J]. Semin Cutan Med Surg, 2009, 28(2): 96-102. [3] Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women [J]. PLoS One, 2012, 7(3): e32955. [4] Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects [J]. Oncologist, 2011, 16(1): 5-24. [5] Dudek-Peric AM, Ferreira GB, Muchowicz A, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin[J]. Cancer Res, 2015, 75(8): 1603-1614. [6] Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer [J]. Nature, 2015, 520(7547): 373-377. [7] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy [J]. Nat Rev Cancer, 2012, 12(4): 252-264. [8] Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami [J]. Nat Rev Drug Discov, 2013, 12(7): 489-492. [9] Fourcade J, Sun Z, Pagliano O, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines [J]. Cancer Res, 2014, 74(4): 1045-1055. [10] Okazaki T, Okazaki IM, Wang J, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice [J]. J Exp Med, 2011, 208(2): 395-407. [11] Menon S, Shin S, and Dy G. Advances in cancer immunotherapy in solid tumors [J]. Cancers (Basel), 2016, 8(12): E106. [12] Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 [J]. Science, 2011, 332(6029): 600-603. [13] Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase Ⅱ study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage Ⅲ or Ⅳ melanoma [J]. Clin Cancer Res, 2009, 15(17): 5591-5598. [14] Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study [J]. Lancet Oncol, 2010, 11(2): 155-164. [15] Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma [J]. N Engl J Med, 2010, 363(8): 711-723. [16] Yamazaki N, Uhara H, Fukushima S, et al. Phase Ⅱ study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma[J]. Cancer Chemother Pharmacol, 2015, 76(5): 969-975. [17] Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial [J]. Lancet Oncol, 2015, 16(5): 522-530. [18] Zimmer L, Eigentler TK, Kiecker F, et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma [J]. J Transl Med, 2015, 13: 351. [19] Alexander M, Mellor JD, McArthur G, et al. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma [J]. Med J Aust, 2014, 201(1): 49-53. [20] Riley JL. PD-1 signaling in primary T cells [J]. Immunol Rev, 2009, 229(1): 114-125. [21] 许标波, 贺毅憬, 王韦力, 等. 肿瘤免疫检查点抑制剂临床治疗的研究进展[J]. 中国临床药理学与治疗学, 2016, 21(2): 218-224. [22] Shi L, Chen S, Yang L, et al. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies [J]. J Hematol Oncol, 2013, 6(1): 74. [23] Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation [J]. J Immunol, 2004, 173(2): 945-954. [24] Ito A, Kondo S, Tada K, et al. Clinical development of immune checkpoint inhibitors [J]. Biomed Res Int, 2015, 2015: 605478. [25] Topalian SL, Drake CG, and Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity [J]. Curr Opin Immunol, 2012, 24(2): 207-212. [26] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer [J]. N Engl J Med, 2012, 366(26): 2443-2454. [27] Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma [J]. JAMA, 2016, 315(15): 1600-1609. [28] Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial [J]. Lancet Oncol, 2015, 16(8): 908-918. [29] Schadendorf D, Dummer R, Hauschild A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma [J]. Eur J Cancer, 2016, 67: 46-54. [30] Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial [J]. Lancet Oncol, 2015, 16(4): 375-384. [31] Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015, 372(26): 2521-2532. [32] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma [J]. N Engl J Med, 2015, 373(1): 23-34. |
| [1] | CHEN Hua, LI Jing, LUO Mei. Effect of salidroside on the growth of oral squamous cell carcinoma cells through regulating NRF2/KEAP1 pathway [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(5): 424-429. |
| [2] | HE Ran, HOU De-qiang. Correlation between perioperative symptom clusters and quality of life in patients with oral and maxillofacial neoplasms [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(5): 446-454. |
| [3] | WANG Xue, ZHANG Ning. Clinical observation of 810 nm diode laser in the treatment of salivary gland mucocele [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(5): 459-462. |
| [4] | HUANG Xin, GUO Zheng-jian, BAO Gang, ZHANG Ting-ting. Peripheral ameloblastoma of gingival soft tissue: a case report [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(5): 510-512. |
| [5] | MAO Chuan-qing, LIN Zhi-lin, LIU Yu, CAI Zhi-yu, CHEN Wei-hui. Epidermoid cysts in free forearm flaps of the buccal region： a case report [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(5): 518-520. |
| [6] | ZHAO Hui, SHU Xin, ZHANG Fan, REN Wei-wei, LIU Jiao, ZHU Zhu. Comprehensive bioinformatics analysis combined with experimental validation to screen biomarkers for head and neck squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(4): 329-338. |
| [7] | GUO Yi-bo, LI Chen-yao, FAN Qi, JI Tong, REN Zhen-hu. Head and neck cancer therapy-induced lymphedema: clinical factors and prognostic analysis [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(4): 360-364. |
| [8] | HUANG Can, LUO Tao, SUN Yu. The predictive value of modified frailty assessment tool for postoperative complications in elderly patients undergoing flap reconstruction with oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(4): 373-377. |
| [9] | GUO Yi-fei, ZHANG Yong-hong, REN Zhen-hu. Diagnosis and treatment of head and neck sarcoma [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(4): 404-408. |
| [10] | LI Chen-xi, FANG Chang, GONG Zhong-cheng, SHAO Bo. Case report of chondromyxofibroma involving the overall structure of the temporomandibular joint: surgical resection and reconstruction [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(4): 409-412. |
| [11] | XU Chen, MA Li-juan, SHI Yao, WEN Yu-zhen, SONG Yong-hai, CHE Zong-gang. Inflammatory myofibroblastic tumor of parotid gland: a case report and literature review [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(4): 413-416. |
| [12] | XI Qi, GAO Wan-peng, LI Huan, ZHAO Qi, WANG Jun, WEI Jian-hua, YANG Xin-jie, YANG Zi-hui. Screening and validation of miRNAs differentially expressed by exosomes of tumor-associated macrophages in microenvironment of salivary gland adenoid cystic carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(3): 209-215. |
| [13] | WANG Rui-jie, MA Hai-long, ZHANG Zhi-yuan. Expression and significance of histone lactylation modifications in head and neck tumors [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(3): 228-232. |
| [14] | HONG Lei, CHEN Wei-liang. Risk factor analysis of postoperative venous thromboembolism in elderly patients with oral cancer [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(3): 233-238. |
| [15] | WANG Min, QIAN Jia-jun, XUE Jun-qing, GU Ting, HU Yu-hua, CHEN Ying, XIA Rong-hui. Analysis of NR4A3 gene rearrangement and NOR-1 protein expression in salivary gland acinic cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(3): 249-254. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
